ClinicalTrials.gg
CompletedNCT00816972Updated Feb 16, 2022

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)

A Phase 2 interventional study of Desloratadine 2.5 mg and Oxybutynin 2.5 mg in Post-nasal Drip, Seasonal Allergic Rhinitis and Rhinorrhea, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.

Sponsored by Organon and Co · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. desloratadine · Rhinitis, Allergic, Seasonal.

Enrollment
3rd of 10
540 · median 272
Started
2005
the only one that year
Phase 2
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
10 of 10
Organon and Co

Among the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal, this one is the 3rd largest by enrollment, is the only one that started in 2005, is the only one in phase 2, and was the 8th registered.

Rhinitis, Allergic, Seasonal

404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.

Browse Rhinitis, Allergic, Seasonal studies →

Open to participants now

None of the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →

About desloratadine

desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal as a file.
02

Study summary

This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.

03

Conditions studied

  • Post-nasal Drip
  • Seasonal Allergic Rhinitis
  • Rhinorrhea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must:

  • be >=18 years of age,
  • be free of any disease that would interfere with study, other than seasonal allergic rhinitis (SAR),
  • have a documented diagnosis of SAR for >=2 years,
  • have had a positive skin-prick test,
  • be sufficiently symptomatic at the Screening visit,
  • for the 3 calendar days immediately prior to baseline visit, plus the AM of the baseline visit, the seven twice-daily run-in diary PRIOR total nasal symptom scores must have totaled >=42, the Total Non-Nasal Symptoms score must have totaled >=28, and the total Post Nasal Drip score must have totaled >=14,
  • be in general good health.

Exclusion criteria

Exclusion Criteria:

Subjects who have:

  • certain medical conditions or medical histories,
  • allergies to any of the components in any of the study medications,
  • nasal structure abnormalities,
  • dependency to nasal, oral, or ocular decongestants, nasal topical antihistamines, or nasal ,
  • used any drug use in past 30 days,
  • received immunotherapy (desensitization)
  • are pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (actual)

Study arms

  • Active comparator
    DL 2.5 mg

    Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days

    Drug: Desloratadine 2.5 mg · Drug: Placebo for Oxybutynin 2.5 mg

  • Active comparator
    OXY 5 mg

    Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days

    Drug: Oxybutynin 2.5 mg · Drug: Placebo for Desloratadine 2.5 mg

  • Experimental
    DL 2.5 mg + OXY 2.5 mg

    Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days

    Drug: Desloratadine 2.5 mg · Drug: Oxybutynin 2.5 mg · Drug: Placebo for Oxybutynin 2.5 mg

  • Experimental
    DL 2.5 mg + OXY 5 mg

    Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days

    Drug: Desloratadine 2.5 mg · Drug: Oxybutynin 2.5 mg

  • Placebo comparator
    Placebo

    Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days

    Drug: Placebo for Desloratadine 2.5 mg · Drug: Placebo for Oxybutynin 2.5 mg

Interventions

  • Desloratadine 2.5 mg BID

    Also known as: SCH 034117, Clarinex

  • Oxybutynin 2.5 mg BID

    Also known as: Ditropan

  • DrugPlacebo for Desloratadine 2.5 mg

    Placebo BID

  • DrugPlacebo for Oxybutynin 2.5 mg

    Placebo BID

06

What researchers measure

Primary outcomes

  1. Change from baseline in mean daily AM/PM Prior post-nasal drip scores averaged over the entire treatment period

    Time frame: Days 1 to 7 +/- 2 days

Secondary outcomes

  1. Anterior rhinorrhea averaged over Days 1 to 8

    Time frame: Days 1 to 8

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2009
First posted
Jan 6, 2009
Start
Apr 2005
Primary completionActual
Jun 2005
CompletionActual
Jun 2005
Last update
Feb 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00816972
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 6, 2009
Start date
Apr 2005
Primary completion
Jun 2005
Completion
Jun 2005
Last update
Feb 16, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Desloratadine · Oxybutynin

Start the discussion